Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review).

ABSTRACT: Lenvatinib (LEN) is a multi-target TKI, which plays a pivotal role in the treatment of advanced hepatocellular carcinoma (HCC). The inevitable occurrence of drug resistance still prevents curative potential and is deleterious for the prognosis, and a growing body of studies is accumulating, which have devoted themselves to unveiling its underlying resistance mechanism and made some progress. The dysregulation of crucial signaling pathways, non-coding RNA and RNA modifications were proven to be associated with LEN resistance. A range of drugs were found to influence LEN therapeutic efficacy. In addition, the superiority of LEN combination therapy has been shown to potentially overcome the limitations of LEN monotherapy in a series of research, and a range of promising indicators for predict

SUBMITTER: Ye G 

PROVIDER: S-EPMC11477829 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature